Free shipping on all orders over $ 500


Cat. No. M10365
L-JNKI-1 Structure
Size Price Availability
5mg USD 333  USD333 1-2 Weeks
10mg USD 487  USD487 1-2 Weeks
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK. L-JNKI-1 has been shown to effectively inhibit JNK activity in in vivo studies. It is shown that Ang II induces a dose-dependent pressor response, which was significantly attenuated by JNK inhibition. It is also found that 10 μM L-JNKI-1 decreases phosphorylated c-Jun by 98% and phosphorylated Elk-1 by 100%.

Chemical Information
Molecular Weight 3822.44
Formula C164H286N66O40
Solubility (25°C) Water 100 mg/mL
Storage -20°C, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Che-Wei Liu, et al. Neuroreport. Stroke injury induced by distal middle cerebral artery occlusion is resistant to N-methyl-d-aspartate receptor antagonism in FVB/NJ mice

[2] Osvaldo Mirante, et al. Int J Mol Sci. Endogenous protease nexin-1 protects against cerebral ischemia

[3] Neil A Turner, et al. Int J Biochem Cell Biol. Human cardiac fibroblasts express ICAM-1, E-selectin and CXC chemokines in response to proinflammatory cytokine stimulation

[4] E Esneault, et al. Neuroscience. D-JNKi, a peptide inhibitor of c-Jun N-terminal kinase, promotes functional recovery after transient focal cerebral ischemia in rats

[5] A Fornoni, et al. Diabetologia. Inhibition of c-jun N terminal kinase (JNK) improves functional beta cell mass in human islets and leads to AKT and glycogen synthase kinase-3 (GSK-3) phosphorylation

Related JNK Products

YL5084, a covalent JNK inhibitor, exhibits selectivity for JNK2 and JNK3 over JNK1 with IC50s of 70 nM, 84 nM and 2173 nM, respectively. YL5084 exhibits JNK2-independent antiproliferative effects and induces apoptosis in a JNK2-independent manner.


SR-3306 is a selective, potent, highly brain penetrant JNK inhibitor.


CC-90001 is a JNK (c-Jun N-terminal kinase) inhibitor that can be used as a Phase II clinical candidate to study idiopathic pulmonary fibrosis.


SU3327 is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM.


L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK.

Abmole Inhibitor Catalog

Keywords: L-JNKI-1 supplier, JNK, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.